See Disclaimer regarding information on this site. Some links on this page may take you to organizations outside of the National Institutes of Health.
cancer-associated retinopathy (CAR), melanoma-associated retinopathy (MAR) and presumed non-paraneoplastic autoimmune retinopathy (npAIR). Autoimmune retinopathy typically presents in the fifth and sixth decades with rapidly progressive, bilateral, painless visual deterioration. Examination of the fundus (the back inner part of the eye) is usually normal at presentation.  The underlying reason for the autoimmune attack on retinal cells remains unknown. Treatment includes systemic immunosuppression with steroid and steroid-sparing agents, intravenous immunoglobulin (IVIG), and plasmapheresis (plasma exchange).Autoimmune retinopathy represents a spectrum of rare autoimmune diseases that primarily affect retinal photoreceptor function and lead to progressive vision loss. Included in this spectrum are
Last updated: 3/11/2014
- Braithwaite T, Vugler A, Tufail A. Autoimmune retinopathy. Ophthalmologica. September 2012; 228(3):131-142. http://www.karger.com/Article/Pdf/338240. Accessed 3/11/2014.
- Maturi RK, Purvin V. Cancer Associated and Related Autoimmune Retinopathies. Medscape Reference. March 5, 2012; http://emedicine.medscape.com/article/1227724-overview. Accessed 3/11/2014.
On this page
- Medscape Reference provides information on this topic. You may need to register to view the medical textbook, but registration is free.
- PubMed is a searchable database of medical literature and lists journal articles that discuss Autoimmune retinopathy. Click on the link to view a sample search on this topic.